Article
Evolution of acute myelogenous leukemia stem cell properties after treatment and progression
15 Jul 2016
Abstract excerpt
Most cancers evolve over time as patients initially responsive to therapy acquire resistance to the same drugs at relapse. Cancer stem cells have been postulated to represent a therapy-refractory reservoir for relapse, but formal proof of this model is lacking. We prospectively characterized leukemia stem cell populations (LSCs) from a well-defined cohort of patients with acute myelogenous leukemia (AML) at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
